Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.

① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.

cls.cnDec 24 17:16

Express News | The USA Biological Security Act was not included in the CR bill.

BreakingsDec 18 15:53

Austar Lifesciences Buys Out Partner in Steris Joint Venture

MT NewswiresDec 17 16:09

Austar Lifesciences Acquires Full Control of Target Company

TipRanksDec 16 22:39

AUSTAR (06118) acquired 51% equity in SteriPharma for 1.515 million USD.

AUSTAR Life Science Technology (06118) announced that on December 16, 2024, the company's wholly-owned subsidiary...

Zhitong FinanceDec 16 22:11

Austar Lifesciences's Subsidiary's Relocation Compensation Agreement With District Committee Terminates

MT NewswiresDec 10 21:00